H.C. Wainwright initiated coverage of Virax Biolabs (VRAX) with a Buy rating and $3 price target Virax is a UK-based development-stage in vitro diagnostics company focused on T cell diagnostics, the analyst tells investors in a research note. The firm says that in the U.S., Virax is slated to meet with the FDA in mid-2025 to define the approval pathway and potentially initiate a U.S.-based clinical validation study in the second half of the year.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRAX:
- Virax Biolabs Launches Clinical Study on T Cell Dysfunction
- Virax Biolabs enrolls first patients in T-cell dysfunction study
- Virax Biolabs Highlights T-Cell Dysfunction in Post-Infection Syndromes
- Virax Biolabs to Present at World Immune Regulation Meeting
- Virax Biolabs Aligns with US Health Department on Vaccine Transparency